Mixed non-specific vaginal infections: the experience with topical therapy
DOI: 10.32364/2618-8430-2020-3-4-221-227
I.O. Borovikov, I.I. Kutsenko, V.P. Bulgakova, E.R. Rubinina, Kh.I. Gorring
Kuban State Medical University, Krasnodar, Russian Federation
Aim: to describe the experience with the topical treatment for mixed non-specific vaginal infections.
Patients and Methods: this prospective study included 72 women (mean age 26.3±5.5 years) with mixed non-specific vaginal infections who received a vaginal capsule containing metronidazole and miconazole (at night for 10 days) followed by a probiotic containing L. casei rhamnosus Doderleini (intravaginally for 14 days). Vaginal microbiota was assessed by real-time PCR. The ratios of Lactobacillus spp. and anaerobic microbe concentrations and the total amount of opportunistic microflora were calculated. In addition, vaginal pH, Hay/Ison criteria, and the sensitivity of Candida spp. to antimycotics (NCCLS standards) were evaluated. When analyzing cellular composition, white blood cell count, epithelial cell count, total cell count, and cytological coefficient were measured. The efficacy was assessed 10 days and 1 month after the treatment.
Results: the treatment resulted in the significant reduction in the clinical (both subjective and objective) symptoms of mixed non-specific vaginal infections, the improvement of vaginal discharge pH and the cellular composition of vaginal discharge and vaginal microbiocenosis. Microscopy with Hay/Ison criteria assessment demonstrated the normalization of Lactobacillus count and the reduction in the threshold of opportunistic microflora and Candida spp.
Conclusions: our experience with the topical treatment for mixed non-specific vaginal infections using a drug containing metronidazole and miconazole has demonstrated high clinical (96%) and microbiological (97.4%) efficacy and safety as well as good treatment compliance.
Keywords: mixed non-specific vaginal infection, decontamination, metronidazole, miconazole, vaginal microbiocenosis, bacterial dysbiosis.
For citation: Borovikov I.O., Kutsenko I.I., Bulgakova V.P. et al. Mixed non-specific vaginal infections: the experience with topical therapy. Russian Journal of Woman and Child Health. 2020;3(4):221–227. DOI: 10.32364/2618-8430-2020-3-4-221-227.
2. Wang Z., Fu L., Xiong Z. et al. Diagnosis and microecological characteristics of aerobic vaginitis in outpatients based on preformed enzymes. Taiwanese J Obstet Gynecol. 2016;55(1):40–44. DOI: 10.1016/j.tjog.2015.06.012.
3. Ibrahimova D.M., Dobrohotova J.E. Approaches to treatment of bacterial vaginosis. Russian Journal of Woman and Child Health. 2018;1(1):1–4 (in Russ.). DOI: 10.32364/2618-8430-2018-1-2-174-177.
4. Borovikov I.O., Kutsenko I.I., Rubinina E.R. Experience of clinical management of mixed urogenital tract infections in women. Russian journal of Woman and Child Health. 2018;1(1):26–32 (in Russ.). DOI: 10.32364/2618-8430-2018-1-1-26-32.
5. Ravel J., Gajer P., Abdo Z., Schneider G. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci USA. 2011;108(1):4680–4687. DOI: 10.1073/pnas.1002611107.
6. Rishchuk S.V. Vaginal Dysbiosis: A New Look at the Problem. Gynecology, obstetrics and perinatology. 2016;15:3:54–63 (in Russ.). DOI: 10.20953/1726-1678-2016-3-54-63.
7. Bebneva T.N., Dobretsova T.A. Mixed vaginal infections: a new ideology. Non-specific vaginal infections in the practice of obstetrician-gynecologist. Newsletter. V.E. Radzinsky, A.M. Savicheva, eds. M.: StatusPraesens; 2016 (in Russ.).
8. Pestrikova T.Y., Yurasova E.A., Kotelnikova A.V., Knyazeva T.P. Current approaches to the verification of bacterial vaginosis diagnosis and treatment tactics. Russian Journal of Woman and Child Health. 2018;2(I):48–53. DOI: 10.31550/1727-2378-2018-150-6-30-33 (in Russ.)].
9. Murashko A.V., Murashko A.A. Bacterial vaginosis: a modern view of the problem. Medical council. 2015;11:80–83 (in Russ.).
10. Kenyon C., Colebunders R., Crucitti T. The global epidemiology of bacterial vaginosis: a systematic review. Am J Obstet Gynecol. 2013;209(6):505–523. DOI: 10.1016/j.ajog.2013.05.006.
11. Sherrard J., Wilson J., Donders G. et al. 2018 European (IUSTI/WHO) International Union against sexually transmitted infections (IUSTI) World Health Organisation (WHO) guideline on the management of vaginal discharge. Int J STD AIDS. 2018;29(13):1258–1272. DOI: 10.1177/0956462418785451.
12. Provotorova T.V. Analysis of long-term results of Metrogyl vaginal gel and Metrogyl plus in the treatment of recurrent vaginal biocenosis disorders. Obstetrics, gynecology and reproduction. 2018;12(2):32–38 (in Russ.). DOI: 10.17749/2313-7347.2018.12.2.032-038.
13. Dobrohotova J.E., Ivanova I.I. Using a combination of metronidazole and myconazole in the correction of vaginal dysbiase. RMJ. Mother and child. 2018;1(1):82–87 (in Russ.). DOI: 10.32364/2618-8430-2018-1-1-82-87.
14. Bitsadze V.O., Radetskaya L.S. Experience of using the local combination product containing miconazole and metronidazole for the treatment of bacterial vaginosis and vulvovaginal candidiasis in pregnant women. Gynecology. 2016;18(6):56–60 (in Russ.).
15. Morisky D., Green L., Levine D. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 2006;24(1):67–74. DOI: 10.12691/ajap-2-5-1.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
